Tag: clinical trials for carcinoid

alexander masters

A Possible Cure for Neuroendocrine Cancer: Exciting Update!

June 19, 2013

Back in September 2012 we shared the following:  “For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor.  At Uppsala University in Sweden researchers are ready to start a …

READ MORE
google alerts creating

8 Easy Steps to Sign Up for Carcinoid Cancer and Neuroendocrine Tumor Google Alerts

January 13, 2013

Do you want to get the latest news about carcinoid and other neuroendocrine tumors delivered directly to your email address? Are you interested in stories about carcinoid/NET survivors, research, clinical trials, blogs, physicians, or organizations? …

READ MORE
pablo lapuerta md

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

December 4, 2012

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

READ MORE
magnus essand

A Possible Cure for Neuroendocrine Cancer — It Can Be Named for You or a Loved One

September 1, 2012

For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor.  At Uppsala University in Sweden researchers are ready to start a clinical trial for up to 20 NET (neuroendocrine tumor)…

READ MORE
lexicon headquarters

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

April 2, 2012

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

READ MORE
glucomedix1

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE